Partner Headlines - TEVA

  1. Insys Therapeutics Q4 beats

    IBD
  2. Insys Therapeutics Q4 Beat Drives Short-Lived Rally

    IBD
  3. Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic ...

    Benzinga
  4. Stocks Hitting 52-Week Highs

    Benzinga
  5. Morning Market Gainers

    Benzinga
  6. Three Reasons To Let Akorn Fall Into Your Portfolio

    IBD
  7. Generic-Drug Makers Soar, And It's Easy To See Why

    IBD
  8. Stocks Rise In Weak Trade; LinkedIn Jumps After Hours

    IBD
  9. Stocks Close Near Session Highs, But Volume Softens

    IBD
  10. Opko Health And Teva Pharmaceutical Industries Surge Following ...

    Benzinga
  11. Analysts are Bullish on IntelliPharmaceuticals Following Deal ...

    GuruFocus
  12. Biotech Stocks Down Despite Strong Amgen Quarter

    IBD
  13. Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's ...

    Benzinga
  14. Benzinga's Weekend M&A Chatter

    Benzinga
  15. Teva Pharmaceutical

    IBD
  16. Sterne Agee Analyst: Court Win To Boost Net At Teva Pharmaceutical

    Benzinga
  17. Jefferies Weighs In On Specialty Pharmaceuticals After Management ...

    Benzinga
  18. US Stock Futures Slip Ahead Of Home Price, Consumer Confidence ...

    Benzinga
  19. OncoGenex to Regain Rights to Custirsen from Teva

    Benzinga
  20. United Therapeutics: Will It Pass Peers In 2015?

    IBD
  21. Teva Upgraded On Strength Of Copaxone MS Drug

    IBD
  22. UPDATE: Sterne Agee Upgrades Teva Pharmaceutical

    Benzinga
  23. Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic ...

    Benzinga
  24. Merck-Cubist Deal Going Ahead Despite Patent Setback

    IBD
  25. Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI

    GuruFocus
  26. Why Opko Health Is a Better Investment Than Apple

    GuruFocus
  27. Benzinga's M&A Chatter for Tuesday November 18, 2014

    Benzinga
  28. Here Are The Top 25 Analysts On Wall Street

    Benzinga
  29. Insys Q3 Beats Estimates, Helping Stock Rebound

    IBD
  30. Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close ...

    Benzinga
  31. Teva ups full-year EPS outlook

    IBD
  32. UPDATE: Teva Posts Stronger-Than-Expected Q3 Profit, Lifts Forecast

    Benzinga
  33. Earnings Scheduled For October 30, 2014

    Benzinga
  34. Lannett Co. Gets Growth Rx In Generic Drugs Group

    IBD
  35. IPO Calendar: Biotech Companies Lead List Of 7 IPOs

    IBD
  36. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  37. Drugmaker M&A Goes On, With Or Without Tax Inversions

    IBD
  38. Actavis Finds Rx To Grow On Busy Drugmaker M&A Scene

    IBD
  39. Teva Reports Results of Strategic Review, Sees 14 Pipeline Projects ...

    Benzinga
  40. Fast Money Halftime Report Final Trade From October 2 - Twitter ...

    Benzinga
  41. Insys Therapeutics Up On Bullish Analyst Initiation

    IBD
  42. Teva Announces UK High Court Gives Positive Judgment In The Company's ...

    Benzinga
  43. 4 Biotechs That Might Be Bought Soon

    IBD
  44. Notable Hedge Funds Disclose Additions And Reductions To Holdings

    Benzinga
  45. Jana Partners LLC Files its 13F

    Benzinga
  46. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  47. Novo Nordisk, Mylan Miss Views; Mallinckrodt Beats

    IBD
  48. Did George Soros Sell His Stake In Israeli Based SodaStream Due ...

    Benzinga
  49. 5 Drug Companies Profiting From Generics

    Benzinga
  50. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  51. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  52. George Soros Reveals His Largest Stake

    GuruFocus
  53. Sofinnova Ventures Closes $500M Fund

    FoxBusiness
  54. Israel's Market Appears Unfazed By Rising Conflict

    IBD
  55. George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps ...

    GuruFocus
  56. UPDATE: Teva Announces FDA Acceptance of NDA For Inhaler

    Benzinga
  57. 4 Top Performing Health Care Stocks With More Potential Upside

    Benzinga
  58. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  59. Top 4 Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  60. Diamond Hill Capital Comments on Teva Pharmaceutical Industries ...

    GuruFocus
  61. Diamond Hill Select Fund Commentary - First Quarter 2014

    GuruFocus
  62. Teva Pharmaceutical

    IBD
  63. Generic-Drug Makers Climb Ranks; Several In Buy Range

    IBD
  64. Teva Turmoil: Shares Up, Board Trimmed, CEO To Retire

    Benzinga
  65. Wells Fargo Initiates Coverage On The Pharmaceutical Space

    Benzinga
  66. Top Guru Held Asian Companies of the First Quarter

    GuruFocus
  67. Teva to buy Labrys Biologics

    IBD
  68. Chicago sues painkiller firms

    IBD
  69. Benzinga's M&A Chatter for Tuesday June 3, 2014

    Benzinga
  70. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  71. Richard Snow's Top Five Highlight Finance and Healthcare Sectors

    GuruFocus
  72. Benzinga's M&A Chatter for Wednesday May 7, 2014

    Benzinga
  73. ETF Outlook For Tuesday May 6, 2014 (EUFN, ITA, EIS, UAE)

    Benzinga
  74. Wrong Marketing Lesson by Big Pharma

    GuruFocus
  75. Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries ...

    Benzinga
  76. Teva EPS tops; rivals seen?

    IBD
  77. Market Wrap For May 1: Markets Mixed To Start The New Month

    Benzinga
  78. Earnings Scheduled For May 1, 2014

    Benzinga
  79. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  80. Actavis Reporting Q1 Earnings Amid Merger Frenzy

    IBD
  81. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  82. Morning Market Losers

    Benzinga
  83. Benzinga's Top #PreMarket Losers

    Benzinga
  84. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase ...

    Benzinga
  85. Nasdaq Could Be in for a Bounce

    FoxBusiness
  86. Actavis got a Pfizer

    IBD
  87. Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received ...

    Benzinga
  88. Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

    Benzinga
  89. Teva Unveils Generic Lunesta Tablets in US

    Benzinga
  90. Teva Announces First Approval and Launch of Generic Lovaza® Capsules ...

    Benzinga
  91. Market Wrap For April 7: Bears In Complete Control As Markets ...

    Benzinga
  92. Citigroup Slaps $70 Price Target on Teva, Highest on Street

    Benzinga
  93. Market Wrap For March 31: Stocks Rally As Yellen Confirms Support ...

    Benzinga
  94. Analyst Offers Insight on Favorable FDA Ruling for Teva Pharma

    Benzinga
  95. Market Wrap For March 28: Markets Still Positive Despite Giving ...

    Benzinga
  96. Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

    Benzinga
  97. UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries

    Benzinga
  98. Forest Laboratories' Recovery

    GuruFocus
  99. Should You Buy Actavis?

    GuruFocus
  100. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
Trading Center